SCHEMBL2365560

SCHEMBL2365560

CN1CCCC1CCn1c2ccccc2c2c3c(ccc21)C(=O)CC3

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.73
ADRA2A P08913 2/20 0.59
RAD52 P43351 1/20 0.42
CAMK2D Q13557 1/20 0.42
SIRT2 Q8IXJ6 1/20 0.42
PRKD3 O94806 1/20 0.41
PRKCG P05129 1/20 0.41
PRKCB P05771 1/20 0.41
PRKCA P17252 1/20 0.41
PRKCH P24723 1/20 0.41
PRKCI P41743 1/20 0.41
PRKCE Q02156 1/20 0.41
PRKCQ Q04759 1/20 0.41
PRKCZ Q05513 1/20 0.41
PRKCD Q05655 1/20 0.41
PRKD1 Q15139 1/20 0.41
HRH1 P35367 3/20 0.39
HRH3 Q9Y5N1 3/20 0.39
HRH2 P25021 1/20 0.39
ADRA1A P35348 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14548900 1.00 TP53 (0.73) TP53ADRA2ARAD52CAMK2DSIRT2
SCHEMBL13637166 0.84 TP53 (1.00) TP53ADRA2APLK1
SCHEMBL13418901 0.84 TP53 (1.00) TP53ADRA2APLK1
SCHEMBL13637360 0.84 TP53 (1.00) TP53ADRA2APLK1
SCHEMBL13418930 0.80 TP53 (0.76) TP53ADRA2ARAD52PRKD3PRKCG
SCHEMBL12608716 0.80 TP53 (0.76) TP53ADRA2ARAD52PRKD3PRKCG
SCHEMBL16131471 0.80 TP53 (0.46) TP53PRKD3PRKCGPRKCBPRKCA
SCHEMBL18975402 0.79 TP53 (0.74) TP53ADRA2APLK1
SCHEMBL18969209 0.79 TP53 (0.74) TP53ADRA2APLK1
SCHEMBL18329007 0.76 TP53 (0.43) TP53ADRA2AHRH1HRH3HRH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190082845-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS INCURON INC (US) 2019-03-21 US disclosed
US-10137109-B2 Carbazole compounds and therapeutic uses of the compounds INCURON, INC. (US) 2018-11-27 US disclosed
US-20170165229-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS INCURON, INC. 2017-06-15 US disclosed
US-20170165229-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS INCURON, INC. 2017-06-15 US disclosed
US-20170165229-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS INCURON, INC. 2017-06-15 US disclosed
US-9566265-B2 Carbazole compounds and therapeutic uses of the compounds INCURON, LLC (US) 2017-02-14 US disclosed
US-9566265-B2 Carbazole compounds and therapeutic uses of the compounds INCURON, LLC (US) 2017-02-14 US disclosed
US-9566265-B2 Carbazole compounds and therapeutic uses of the compounds INCURON, LLC (US) 2017-02-14 US disclosed
US-20150342927-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS INCURON, INC. 2015-12-03 US disclosed
US-20150342927-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS INCURON, INC. 2015-12-03 US disclosed
US-8765738-B2 Carbazole compounds and therapeutic uses of the compounds INCURON, LLC (US) 2014-07-01 US disclosed
US-8765738-B2 Carbazole compounds and therapeutic uses of the compounds INCURON, LLC (US) 2014-07-01 US disclosed
EP-2356093-B1 Carbazole compounds and therapeutic uses of the compounds INCURON LLC (RU) 2013-01-09 EP disclosed
EP-2356093-B1 Carbazole compounds and therapeutic uses of the compounds INCURON LLC (RU) 2013-01-09 EP disclosed
US-20110305661-A1 Carbazole Compounds and Therapeutic Uses of the Compounds INCURON, INC. 2011-12-15 US disclosed
US-20110305661-A1 Carbazole Compounds and Therapeutic Uses of the Compounds INCURON, INC. 2011-12-15 US disclosed
US-20110305661-A1 Carbazole Compounds and Therapeutic Uses of the Compounds INCURON, INC. 2011-12-15 US disclosed
EP-2356093-A1 Carbazole compounds and therapeutic uses of the compounds INCURON, LLC (RU) 2011-08-17 EP disclosed
WO-2010042445-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS CLEVELAND BIOLABS, INC. (US) 2010-04-15 WO disclosed
WO-2010042445-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS CLEVELAND BIOLABS, INC. (US) 2010-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170165229-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS MALT1, PAICS, BCL9 TP53 28/4885ADRA2A 3619/4885RAD52 4164/4885
US-20150342927-A1 CARBAZOLE COMPOUNDS AND THERAPEUTIC USES OF THE COMPOUNDS MALT1, PAICS, BCL9 TP53 28/4885ADRA2A 3619/4885RAD52 4164/4885
US-10137109-B2 Carbazole compounds and therapeutic uses of the compounds MALT1, PAICS, BCL9 TP53 28/4885ADRA2A 3619/4885RAD52 4164/4885
US-20110305661-A1 Carbazole Compounds and Therapeutic Uses of the Compounds MALT1, PAICS, TPMT TP53 33/4885ADRA2A 3580/4885RAD52 4251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.